Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.

Fiche publication

Date publication

janvier 2022

Journal

Journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34982200

Résumé

Exit strategy after natalizumab cessation in multiple sclerosis (MS) is a crucial point because the risk of disease reactivation is high during this period. The objective of this observational study was to compare ocrelizumab to fingolimod after natalizumab cessation in patients with relapsing-remitting multiple sclerosis (RRMS).